Characterization of muscarinic receptor subtypes that mediate antinociception in the rat spinal cord

Anesthesia and Analgesia

Volumn 85, Issue 4, 1997, Pages 847-853

  Naguib, Mohamed ^a   Yaksh, Tony L ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; ATROPINE; CARBACHOL; HEMICHOLINIUM 3; METHOCTRAMINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEOSTIGMINE; PIRENZEPINE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; SPINAL CORD;

EID: 0030809983     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199710000-00025     Document Type: Article

References (27)

1. Yaksh TL, Dirksen R, Harty GJ. Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol 1985;117:81-8.
2. Smith MD, Yang X, Nha J-Y, Buccafusco JJ. Antinociceptive effect of spinal cholinergic stimulation: interaction with substance P. Life Sci 1989;45:1255-61.
3. Gillberg PG, Gordh T Jr, Hartvig P, et al. Characterization of the antinociception induced by intrathecally administered carbachol. Pharmacol Toxicol 1989;64:340-3.
4. Naguib M, Yaksh TL. Antinociceptive effects of spinal cholinesterase inhibition and isobolographic analysis of the interaction with μ and α2 receptor systems. Anesthesiology 1994;80: 1338-48.
5. Hammer R, Berrie BC, Birdsall NJM, et al. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980;283:90-2.
6. Doods HN, Mathy M-J, Davidesko D, et al. Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 1987;242:257-62.
7. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527-32.
8. Kubo T, Fukuda K, Mikami A, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986;323:411-6.
9. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat M5 muscarinic acetylcholine receptor genes. Neuron 1988;1:403-10.
10. Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 1989;35:469-76.
11. Lazareno S, Buckley NJ, Roberts FF. Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG 108-15 cells. Mol Pharmacol 1990;38:805-15.
12. Hammer R, Giachetti A. Muscarinic receptors subtypes M1 and M2: biochemical and functional characterization. Life Sci 1982; 31:2991-4.
13. 3H]-quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes. J Pharmacol Exp Ther 1986;237:411-8.
14. Eglen RM, Whiting RL. Muscarinic receptors subtypes: a critique of the current classification and a proposal for a working nomenclature. J Auton Pharmacol 1986;5:323-46.
15. Hu J, El-Fakahany EE. Selectivity of McN-A-343 in stimulating phosphoinositide hydrolysis mediated by M1 muscarinic receptors. Mol Pharmacol 1990;38:895-903.
16. Kenakin TP. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 1984;36:165-222.
17. Michel AD, Whiting RL. Methoctramine, a polymethylene tetraamine, differentiates three subtypes of muscarinic receptor in direct binding studies. Eur J Pharmacol 1988;145:61-6.
18. 3H]4DAMP. Eur J Pharmacol 1989; 166:459-66.
19. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976;17:1031-6.
20. Hargreaves K, Dubner R, Brown F, et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
21. Bartolini A, Ghelardini C, Fantetti L, et al. Role of muscarinic receptor subtypes in central antinociception. Br J Pharmacol 1992;105:77-82.
22. Gilbert R, Rattan S, Goyal RK. Pharmacologic identification, activation and antagonism of two muscarine receptor subtypes in the lower esophageal sphincter. J Pharmacol Exp Ther 1984; 230:284-91.
23. Bloom JW, Halonen M, Seaver NA, Yamamura HI. Heterogeneity of the M1 muscarinic receptor subtype between peripheral lung and cerebral cortex demonstrated by the selective antagonist AF-DX 116. Life Sci 1987;41:491-6.
24. Choo LK, Mitchelson F. Selective inhibition of responses to carbachol and McN-A-343 in the rabbit vas deferens. Clin Exp Pharmacol Physiol 1990;17:601-11.
25. Ghelardini C, Malmberg-Aiello P, Giotti A, et al. Investigation into atropine-induced antinociception. Br J Pharmacol 1990;101: 49-54.
26. Pitler TA, Alger BE. Activation of the pharmacologically defined M3 muscarinic receptor depolarizes hippocampal pyramidal cells. Brain Res 1990;534:257-62.
27. Martin JR. Pressor response to posterior hypothalamic administration of carbachol is mediated by muscarinic M3 receptor. Eur J Pharmacol 1992;215:83-91.